The Serenity Test for Pregnant Women: Non-Invasive Prenatal Testing

10+ weeks

Pioneers of Genetic Diagnosis

Genesis Genetics is the pioneer of pre-implantation testing of embryos for inherited genetic abnormalities. Genesis Genetics was founded by world-renowned scientists who are largely responsible for founding pre-implantation genetic diagnosis (PGD) as a clinical practice. Our PGD team performed one of the first successful PGD cases.

To date, Genesis Genetics has performed thousands of cases of PGD. The organization is recognized as the leader in the industry and is the top choice for people seeking to build their families through the miracle of PGD. We work with hundreds of domestic and international IVF clinics. We have earned the reputation as the most trusted laboratory performing PGD and also pre-implantation genetic screening (PGS) on a global scale.

The Genesis Serenity non-invasive prenatal test (NIPT) uses verifi™ test technology developed by Illumina, the world largest DNA sequencing company. The Genesis Serenity prenatal test measures genetic material (or DNA) from a pregnant woman™s blood to look for too few or too many copies of chromosomes in the mother and baby. Missing or extra copies of chromosomes are referred to as ™aneuploidies™ and may be related to conditions in pregnancy where an extra chromosome is present such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), or trisomy 13 (Patau syndrome).

Our team of genetic counsellors, molecular geneticists, physicians and administrative staff work closely with your reproductive doctors to fulfil our mission: helping build healthy families. Throughout our locations in the United States, Brazil, England, South Africa, Jordan and Taiwan, Genesis Genetics has helped thousands of families achieve their desire for a healthy infant. Their photographs cover our walls and their stories inspire us.


Click here to visit: SERENITY™ test for Patients

TEST Serenity™
Company website
COMPANY Genesis Genetics
Test Origin USA
Laboratory Location UK: London
Type of cfDNA analysis Massively parallel genomic sequencing
Screen Population GENERAL & HIGH RISK
Number of tests performed >250,000
Clinical data number re test performance 34,306
About the test
Gestational age 10+ weeks
Pregnancies Screened
Naturally conceived YES
IVF (Self) YES
IVF (Donor) YES
Multiples (Twins)
Naturally conceived YES
IVF (Self) YES
IVF (Donor) YES
Risk analysis Aneuploid detected / not detected / suspected plus high / low risk result
Fetal fraction redraw level <1.4%
Fetal fraction quoted NO
Redraw rate 0.1%
Chance of result after 2nd blood sample 99%
Chromosomes analysis Current Validated Detection Rates 01/06/2015
Combined false positive rate T12/T18/T13 0.2%
T21 Down’s syndrome >99%
T18 Edwards’ syndrome >98%
T13 Patau’s syndrome >98%
Triploidy n/a
Fetal sex / presence of Y chromosome: accuracy YES:>99% (inc Twins)
Sex Aneuploid Conditions Y aneuploidy (optional no extra charge)
X0 (Turner syndrome) YES (Singleton only)
XXX (Triple X) YES (Singleton only)
XYY (Jacob™s syndrome) YES (Singleton only)
XXY (Klinefelter syndrome) YES (Singleton only)
Micro deletions (Optional) YES (Additional Charge +£100)
Turnaround Time (TAT) working days 3 to 5